Million

<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noreferrer noopener" class="deco-link">website policy</a>&nbsp;prior to making financial decisions.
</div> 
<p class="has-drop-cap">Bioventus Inc. (NASDAQ: BVS), a leading innovator in active healing solutions, showcased robust financial performance for the fourth quarter of 2023, as delineated in its <a aria-label="latest earnings report (opens in a new tab)" href="https://ir.bioventus.com/news-releases/news-release-details/bioventus-announces-fourth-quarter-and-full-year-2023-financial" target="_blank" rel="noreferrer noopener nofollow" class="deco-link">latest earnings report</a>. </p> 
<p>Bioventus reported a remarkable surge in its fourth-quarter sales growth, achieving a 7.6% increase in worldwide revenue, totaling $135.4 million compared to the prior year. This growth is particularly impressive considering the organic revenue increase of 14.3%, driven by significant advancements in Pain Treatments and Surgical Solutions, which saw over 20% growth. <br><br>Additionally, the company significantly reduced its net loss from continuing operations to $7.7 million from $35.4 million in the previous year, showcasing effective cost management and operational efficiencies. Adjusted EBITDA from continuing operations also saw a commendable increase of 28.1%, reaching $22.0 million due to disciplined cost management alongside revenue growth.</p> 
<h3 id="bioventus-smashes-expectations-in-q4-with-135-4-million-in-revenue">Bioventus Smashes Expectations in Q4 with $135.4 Million in Revenue</h3> 
<p>Bioventus’s fourth-quarter performance exceeded expectations on several fronts. Analysts had projected earnings per share (<a href="https://tokenist.com/investing/how-to-value-a-stock/" rel="dofollow" class="deco-link">EPS</a>) of $0.019 and revenue of $123.96 million for the quarter. The results outstripped these expectations, with the company reporting non-GAAP earnings per share from continuing operations of $0.07 and total revenue of $135.4 million. This performance underscores the company’s ability to exceed financial projections and highlights its strong market presence and operational execution.</p> 
<div class="cta-referral"> 
 <img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" class="cta-referral__img" loading="lazy" decoding="async"> 
 <div class="cta-referral__text"> 
  <p>Join our&nbsp;<a href="https://t.me/thetokenist" target="_blank" rel="noreferrer noopener nofollow" class="deco-link">Telegram group&nbsp;and never miss a breaking story.</a></p> 
 </div> 
</div> 
<h3 id="guidance">Guidance</h3> 
<p>Looking forward, Bioventus has provided an optimistic financial outlook for the full year of 2024, reflecting confidence in its strategic initiatives and market opportunities. The company expects net sales to range between $520 million to $535 million and adjusted EBITDA to be near $89 million to $94 million. Furthermore, the non-GAAP EPS is projected to be between $0.12 to $0.20. </p> <iframe src="https://tokenist.substack.com/embed" width="100%" height="320" style="border:1px solid #EEE; background:white;" frameborder="0" scrolling="no"></iframe> 
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em></p> 
<h3 id="br"><br></h3> 
<p>The post <a rel="nofollow" href="https://tokenist.com/bioventus-surges-with-7-6-q4-revenue-growth-to-135-4m-outstripping-expectations/">Bioventus Surges with 7.6% Q4 Revenue Growth to $135.4M, Outstripping Expectations</a> appeared first on <a rel="nofollow" href="https://tokenist.com">Tokenist</a>.</p>

Bioventus Surges with 7.6% Q4 Revenue Growth to $135.4M, Outstripping Expectations

Table of Contents

Tokenist

Other articles published on Mar 12, 2024

Ethereum’s Dencun upgrade vital to network’s future

Chainge (XCHNG) Price Prediction 2025, 2026, 2027, 2028, 2029 and 2030

ChatGPT Named Cardano, Polygon, and BlastUP as Price Rally Winners of March

Singapore Traders Fair and Blockchain Fest: A Day of Triumph and Innovation!

Profits Surge: Stacks & Bitcoin Cash Investors Shift Into Kelexo (KLXO) Presale For Long-Term Gains

Avalanche Upholding Gains; Will AVAX Price Skyrocket Above $50?

Join our free newsletter for daily crypto updates!